By the cruel calculus of the AIDS epidemic, the best anti-AIDS drugs almost never reach the millions of people who need them most. In the face of the widespread epidemic in sub-Saharan Africa--where more than 25 million people are HIV positive--pharmaceutical companies have been under increasing pressure to supply the developing world with cut-rate medicines. But no matter how much they trim prices on a combination-drug regimen that can cost $15,000 a year in the U.S., it's never quite enough to make a dent in countries where per capita annual income is only a few hundred dollars.
Now the deadly...
To continue reading:
or
Log-In
